Alluvi tirzepatide appears to have emerged as a promising therapeutic candidate for the management of metabolic diseases. This exploratory evaluation investigated the efficacy and tolerability of tirzepatide 40mg in experimental models of insulin resistance. The experiments demonstrated that tirzepatide 40mg substantially improved glycemic control